News Summary

Vancouver-based Aspect Biosystems has successfully secured a $115-million USD ($165 million CAD) Series B funding round, propelling its 3D-printed tissue therapies closer to clinical trials. The startup aims to revolutionize medical treatments by bioprinting healthy cells and tissues to address diseases like Type 1 diabetes and liver diseases. The funding was led by Dimension, with participation from investors such as Toronto-based Radical Ventures and Danish pharmaceutical giant Novo Nordisk. This investment will support Aspect’s transition from pre-clinical to clinical-stage development, allowing it to bring its innovative tissue implants to human trials. The company is also backed by a public sector initiative, planning to establish Canada’s first clinical biomanufacturing facility with a $200-million investment from the BC and federal governments. Despite the challenging biotech funding landscape in Canada, Aspect remains committed to maintaining its operations locally while targeting global market growth.